Apellis Pharmaceuticals, Inc. (APLS)
APLS moved a median of -0.17% 30 minutes after news, and -0.25% by the close. How APLS actually reacts to news — the realized, point-in-time move the market made, measured across 714 labeled events over the last three years with zero look-ahead.
APLS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 678 |
| 30-min | -0.17% | 44% | 678 |
| 60-min | -0.16% | 45% | 678 |
| to close | -0.25% | 44% | 676 |
| Middle 50% of APLS reactions | -0.99% to +0.81% |
|---|---|
| Median reaction (30-min) | -0.17% |
| Measured reactions | 714 |
Half of all Apellis Pharmaceuticals, Inc. news events land between -0.99% and +0.81% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How APLS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | +1.52% | 63% | +1.13% |
| Analyst downgrades | 40 | +0.09% | 85% | +0.07% |
| Coverage initiations | 32 | +0.17% | 59% | -0.47% |
| Rating reiterations | 146 | -0.32% | 38% | -0.09% |
| Price-target raises | 34 | +0.30% | 56% | +0.30% |
| Price-target cuts | 51 | -0.42% | 35% | -0.30% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how APLS ranks against every other measured name →
That’s how APLS usually reacts — get an email when it moves on news →Email me when APLS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APLS's baseline. Nothing else.
Recent APLS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Apellis Pharmaceuticals, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K Apellis Pharmaceuticals, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-8 POS Apellis Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600 | Press release | PR Newswire | -0.01% | +0.02% | |
| Form 10-Q Apellis Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.05% | +0.07% | |
| Form 8-K Apellis Pharmaceuticals, For: Apr 28 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +0.02% | |
| Form 10-K/A Apellis Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.02% | +0.12% | |
| Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.02% | +0.05% | |
| Are GSAT, APLS, FORA Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | -0.01% | |
| Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | +0.23% | |
| Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.02% | +0.01% | |
| Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders | Press release | GlobeNewswire | +0.03% | +0.11% | |
| APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +0.05% | -0.40% | |
| Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.01% | -0.16% | |
| Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology | Press release | GlobeNewswire | +0.05% | -0.40% | |
| Form 8-K Apellis Pharmaceuticals, For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | +0.07% | |
| Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors | Press release | GlobeNewswire | +1.77% | +1.82% | |
| Form 8-K Apellis Pharmaceuticals, For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | +1.77% | +1.82% | |
| Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.34% | +5.78% | |
| Form 10-K Apellis Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.34% | +5.78% | |
| Form S-8 Apellis Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | -1.34% | +5.78% | |
| Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference | Press release | GlobeNewswire | +1.26% | +1.40% | |
| Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting | Press release | GlobeNewswire | -0.97% | +3.40% | |
| Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.13% | -2.34% | |
| Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -5.26% | -12.15% | |
| Form 8-K Apellis Pharmaceuticals, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.92% | -6.49% | |
| Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.08% | -3.68% | |
| The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN | Press release | GlobeNewswire | +1.56% | +4.62% | |
| Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.90% | +4.74% | |
| Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years | Press release | GlobeNewswire | +1.44% | +3.09% | |
| Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference | Press release | GlobeNewswire | +0.00% | -2.68% | |
| Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.60% | -16.58% | |
| Form 10-Q Apellis Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.60% | -16.58% | |
| New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week | Press release | GlobeNewswire | -0.24% | +7.68% | |
| Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.42% | -4.24% | |
| Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.91% | +1.07% | |
| Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +5.42% | +8.18% | |
| Form 10-Q Apellis Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.42% | +8.18% | |
| FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older | Press release | GlobeNewswire | -0.29% | — | |
| Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.13% | +0.70% | |
| Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting | Press release | GlobeNewswire | -0.92% | -3.78% | |
| Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) | Press release | GlobeNewswire | +0.56% | -0.17% | |
| Form 8-K Apellis Pharmaceuticals, For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.56% | -0.17% | |
| Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN | Press release | GlobeNewswire | -0.52% | -0.26% | |
| Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.79% | -2.32% | |
| Form 8-K Apellis Pharmaceuticals, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +3.24% | |
| Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results | Press release | GlobeNewswire | -0.06% | +4.84% | |
| Form 10-Q Apellis Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.06% | +4.84% | |
| Apellis Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.86% | -3.24% | |
| Apellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.55% | +5.90% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APLS section they belong to.
Where else APLS is measured.
APLS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ESSA Pharma Inc. (EPIX) | 718 | 0.00% | 38% |
| Tricida, Inc. (TCDA) | 715 | +0.06% | 51% |
| Enochian Biosciences, Inc. (ENOB) | 712 | 0.00% | 42% |
| LIFEPOINT HEALTH INC COMMON (LPNT) | 709 | +0.01% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Apellis Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled APLS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 714 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of APLS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APLS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.